Page 13 - Haematologica May 2022

Editorials
royalties from UpToDate, and his institution has received research support on his behalf from Alexion, Bayer, Novartis, Novo Nordisk, Pfizer, Sanofi, and Spark.
Contributions
Both authors contributed equally.
References
1. Bernal JL, Andrews N, Gower C, et al. Effectiveness of Covid-19 vac- cines against the B.1.617.2 (delta) variant. New Engl J Med. 2021;385(7):585-594.
2. Lee E, Cines DB, Gernsheimer T, et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol. 2021;96(5):534-537.
3. Choi PY, Hsu D, Tran HA, et al. Immune thrombocytopenia following vaccination during the COVID-19 pandemic. Haematologica. 2022;107(5):1193-1196.
4. Ritchie H, Ortiz-Ospina E, Beltekian D, et al. Coronavirus pandemic
(COVID-19). https://ourworldindata.org/coronavirus.
5.Simpson CR, Shi T, Vasileiou E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboem- bolic and hemorrhagic events in Scotland. Nat Med. 2021;27(7):1290-
1297.
6. Pottegård A, Lund LC, Karlstad Ø, et al. Arterial events, venous throm-
boembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: popula- tion based cohort study. BMJ. 2021;373:n1114.
7. Welsh KJ, Baumblatt J, Chege W, Goud R, Nair N. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID- 19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2021;39(25): 3329-3332.
8. Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol. 2009;145(2):235-244.
9. Moulis G, Guénin S, Limal N, et al. Seasonal variations of incident pri- mary immune thrombocytopenia in adults: an ecological study. Eur J Intern Med. 2017;37:e26-e28.
10. Cines DB, Bussel JB, Liebman HA, Prak ETL. The ITP syndrome: path- ogenic and clinical diversity. Blood. 2009;113(26):6511-6521.
haematologica | 2022; 107(5)
1021